Shenzhen Jianyuan Pharmaceutical Technology

Shenzhen Jianyuan Pharmaceutical Technology is a specialized biotechnology company focused on the research, development, and large-scale production of peptide-based pharmaceuticals. As a key subsidiary of Shenzhen Hybio Pharmaceutical, the company leverages advanced peptide synthesis technologies to manufacture high-quality Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Their portfolio includes significant treatments for metabolic diseases, such as Liraglutide and Semaglutide, as well as therapies for osteoporosis and gastrointestinal conditions. Jianyuan operates state-of-the-art manufacturing facilities that comply with international GMP standards, positioning itself as a critical player in the global peptide drug supply chain. The company provides both proprietary products and CDMO services to global pharmaceutical partners.